Guggenheim Initiates Coverage On Entera Bio with Buy Rating, Announces Price Target of $11
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsInitiationPrice Target
Guggenheim analyst Vamil Divan initiates coverage on Entera Bio (NASDAQ:ENTX) with a Buy rating and announces Price Target of $11.
Guggenheim analyst Vamil Divan initiates coverage on Entera Bio (NASDAQ:ENTX) with a Buy rating and announces Price Target of $11.